Alcidion Group Limited · ASX:ALC
Alcidion — FY2020 Earnings Presentation
20 slides from Alcidion's earnings presentation, Sep 9, 2020
Slide 1: FY2020 Results Presentation
9 September 2020 Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 FY2020 Results Presentation Melbourne, Victoria - Alcidion Group Limited (ASX: ALC) today releases the attached FY2020 results investor presentation that will be presented to investors this week by Managing Director Kat
Slide 2: Investor Presentation: FY20 Full Year Results Update
Investor Presentation FY20 Full Year Results Update Kate Quirke, Group Managing Director September 2020 COMMERCIAL IN CONFIDENCE 1
Slide 3: Health informatics company enabling healthcare organisations to transform healthcare delivery
Health informatics company enabling healthcare organisations to utilise technology to transform Click Here to Play Introductory Video healthcare delivery • Unique software & service offering to support safer & smarter healthcare delivery • Targeting three core geographies: • Australia • New Zealand
Slide 4: Solid growth achieved in FY20 despite a challenging environment
Solid growth achieved in FY20 despite a challenging environment $18.6M $12.8M 35% REVENUE DELIVERED IN PRESOLD REVENUE FOR INCREASE IN RECURRING FY2020, 10% INCREASE ON FY21, 9% INCREASE ON REVENUE BASE ON FY2019 FY2019 PRIOR YEAR $16.2M $15.9M $1B+ RAISED IN NOVEMBER CASH RESERVES AT 30 JUNE GROWIN
Slide 5: Supporting healthcare providers through COVID-19
Supporting healthcare providers through COVID-19 • COVID-19 pandemic created significant challenges for healthcare Customers using Miya Precision for remote organisations, as providers were forced at short notice to quickly adopt measures to deal with the impact of the virus monitoring of COVID-19 p
Slide 6: Financials
Financials COMMERCIAL IN CONFIDENCE 5
Slide 7: FY2020 Financial Highlights
FY2020 Financial Highlights • 10% revenue growth achieved in FY2020 despite Total sold revenue - YTD FY2020 revenue challenging environment in second half due to 20 FY2019 revenue $16.9M $18.6M COVID-19 15 • Recurring revenue base increased 35% on prior 10 14.8 15.9 15.4 17.4 year 5 11.1 12.9 • Stro
Slide 8: Profit & Loss (Pro Forma)
Profit & Loss (Pro Forma) 1 Key Comments Profit & Loss ($A000s) FY19 FY20 Recurring 7,824 10,459 • 10% pcp revenue growth, despite experiencing delays of some contracts as a Non-recurring 9,040 8,150 result of COVID-19 in H2’20 • 56% revenue attributable to Products (Miya Precision, Patientrack, Sma
Slide 9: Revenue Breakdown
Revenue Breakdown Licence + M&S1 recurring revenue underpin future growth, supported by implementation & service fees benefiting current cash flow Core Offering Products ~80%2 Technical Services ~20%2 Key Product / Miya Precision, Patientrack, Smartpage Data analytics, Integration, interoperability
Slide 10: Cash Flow
Cash Flow Key Comments Cash Flow Statement (A$000's) FY19 FY20 Cash flows from operating activities • Strong cash balance of $15.9M at 30 June 2020, raised $16.2m via Placement Receipts from customers 16,469 20,543 in November 2019 Payments to suppliers and employees (14,494) (22,556) Interest recei
Slide 11: Growth Strategy Update
Growth Strategy Update COMMERCIAL IN CONFIDENCE 10
Slide 12: FY2020 Operational Highlights
FY2020 Operational Highlights A year of solid progress – expanded user base, product evolution & scale up • Growing customer base, with key Miya Precision Significant contracts signed in FY2020 reference sites across UK, Australia & NZ • UK scale up underway, key sales & marketing hires in place sup
Slide 13: Delivering on our growth strategy
Delivering on our growth strategy • Key hires in Sales & Marketing made in each market • Solid early results – new contract signings & enhanced sales capability Accelerate growth in existing markets • UK marketing launch of Miya Precision in September 2020 • Supported by accelerated marketing strate
Slide 14: UK Market Update
UK Market Update Current market presence Key reference sites Market Dynamics • Government-led investment in digital health 18 NHS Trusts as part of NHS reform 45 Hospitals • Mix of integrated EMR and Best of Breed solutions 145,000 • Increasing frameworks established for efficient digital health pro
Slide 15: Australia Market Update
Australia Market Update Current market presence Key reference sites Market Dynamics • Healthcare services moving to integrated 33 Customers models of care 236 Hospitals • Digital health a core part of investment in integrated care model • Government digital health spend currently 63,000 $2Bn & set t
Slide 16: New Zealand Market Update
New Zealand Market Update Current market presence Key reference sites Market Dynamics • Miya Observations & Assessments clear 18 District Health Boards market leader for patient observations in 45 Hospitals South Island & Northern Region DHBs • Best of Breed solutions more commonly used over EMRs 10
Slide 17: Outlook
Outlook COMMERCIAL IN CONFIDENCE 16
Slide 18: Poised for growth in FY2021
Poised for growth in FY2021 FY2021 FY2020 Sold revenue as at Sold revenue as at • Cash reserves of $15.9M at 30 June 2020 to 30 June 2020 30 June 2019 (PCP) support planned investment, cost base to Recurring vs Non- Recurring vs Non- stabilise in FY21 recurring ($M) Recurring ($M) 15 15 • $12.8M sol
Slide 19: Disclaimer
Disclaimer This presentation has been prepared by Alcidion Group Limited (‘Alcidion’). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requ
Slide 20: Contacts
Contacts Kyahn Williamson Group Head: Corporate and Investor Communication WE Communications Kwilliamson@we-worldwide.com +61 401 018 828 19